These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 35483156)
1. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis. She L; Tian K; Han J; Zuo W; Wang Z; Zhang N Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156 [TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D; Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888 [TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Burtness B; Rischin D; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Brana I; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesia R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Ge J; Swaby RF; Gumuscu B; Harrington K J Clin Oncol; 2022 Jul; 40(21):2321-2332. PubMed ID: 35333599 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. Wurcel V; Chirovsky D; Borse R; Altuna JI; Carabajal F; Gandhi J Adv Ther; 2021 May; 38(5):2613-2630. PubMed ID: 33855690 [TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. Zhou K; Li Y; Liao W; Zhang M; Bai L; Li Q Oral Oncol; 2020 Aug; 107():104754. PubMed ID: 32428689 [TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Harrington KJ; Burtness B; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Brana I; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesia R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Lin J; Gumuscu B; Swaby RF; Rischin D J Clin Oncol; 2023 Feb; 41(4):790-802. PubMed ID: 36219809 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More. Zheng Z; Lin J; Zhu H; Cai H Front Public Health; 2022; 10():893387. PubMed ID: 35774581 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Lang Y; Dong D; Wu B Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408 [TBL] [Abstract][Full Text] [Related]
11. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis. Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial. Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020 [TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study. Zhan M; Xu T; Zheng H; He Z Front Public Health; 2022; 10():790225. PubMed ID: 35309225 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis. Ye D; Liang X; Chen X; Li Y Sci Rep; 2024 Mar; 14(1):6807. PubMed ID: 38514766 [TBL] [Abstract][Full Text] [Related]
16. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048. Takahashi S; Oridate N; Tanaka K; Shimizu Y; Fujimoto Y; Matsumoto K; Yokota T; Yamazaki T; Takahashi M; Ueda T; Hanai N; Yamaguchi H; Hara H; Yoshizaki T; Yasumatsu R; Nakayama M; Shiga K; Fujii T; Mitsugi K; Takahashi K; Nohata N; Gumuscu B; Swaby RF; Tahara M Int J Clin Oncol; 2022 Dec; 27(12):1805-1817. PubMed ID: 36264378 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231 [TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels. Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]